Orrick advised SFJ Pharmaceuticals on the deal. SFJ Pharmaceuticals (“SFJ”) announced its acquisition of assets related to Bentracimab, a drug with the potential to address a significant...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
